A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma

NCT03166878 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

80

Enrollment

OTHER

Sponsor class

Conditions

B Cell Leukemia
B Cell Lymphoma

Interventions

BIOLOGICAL: UCART019

Sponsor

Chinese PLA General Hospital